Use of bone turnover markers in the management of osteoporosis

被引:69
作者
Jain, Sumeet [1 ]
Camacho, Pauline [1 ]
机构
[1] Loyola Univ Med Ctr, 2160 S 1st Ave, Maywood, IL 60153 USA
关键词
bone turnover markers; C-terminal telopeptide of type I collage; N-terminal propeptide of type I collagen; osteoporosis; REFERENCE INTERVALS; BIOCHEMICAL MARKERS; POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN; VERTEBRAL FRACTURE; GLUCOSE-TOLERANCE; MINERAL DENSITY; GLA-PROTEIN; FOLLOW-UP; RESORPTION;
D O I
10.1097/MED.0000000000000446
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Osteoporosis is a common public health problem that is often undertreated and underdiagnosed. The clinical management of osteoporosis is often reactionary to devastating fracture events. Bone turnover markers may improve the ease and rapidity at which osteoporosis is monitored and treated. Bone turnover markers are biochemical byproducts of bone formation or bone resorption. The clinical use of bone turnover markers is limited by significant preanalytical variability. Effective interpretation of bone turnover markers requires a detailed understanding of the variables that can affect their responses to osteoporosis treatment and monitoring. Recent findings Progress is continuously being made on the standardization of bone turnover markers. The literature on the response of bone turnover markers to unique clinical situations is expanding. Data for evidence-based reference intervals for bone turnover markers has increased. Variables that affect the appropriate timing of lab draws like diurnal variation, postprandial status, exercise and alcohol use have been described. Studies examining the expected response of bone turnover markers to treatments of osteoporosis and other medications that affect bone health continue to increase. Bone turnover markers have clinical utility in the comprehensive evaluation of osteoporosis. When interpreted with caution and with a good understanding of their natural variability, bone turnover markers provide information that supplements osteoporosis management and provides useful clinical information about conditions that alter bone turnover.
引用
收藏
页码:366 / 372
页数:7
相关论文
共 71 条
[51]   Reference intervals for serum concentrations of three bone turnover markers for men and women [J].
Michelsen, J. ;
Wallaschofski, H. ;
Friedrich, N. ;
Spielhagen, C. ;
Rettig, R. ;
Ittermann, T. ;
Nauck, M. ;
Hannemann, A. .
BONE, 2013, 57 (02) :399-404
[52]   Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis A Randomized Clinical Trial [J].
Miller, Paul D. ;
Hattersley, Gary ;
Riis, Bente Juel ;
Williams, Gregory C. ;
Lau, Edith ;
Russo, Luis Augusto ;
Alexandersen, Peter ;
Zerbini, Cristiano A. F. ;
Hu, Ming-yi ;
Harris, Alan G. ;
Fitzpatrick, Lorraine A. ;
Cosman, Felicia ;
Christiansen, Claus .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (07) :722-733
[53]   Clinical usefulness of bone turnover marker concentrations in osteoporosis [J].
Morris, H. A. ;
Eastell, R. ;
Jorgensen, N. R. ;
Cavalier, E. ;
Vasikaran, S. ;
Chubb, S. A. P. ;
Kanis, J. A. ;
Cooper, C. ;
Makris, K. .
CLINICA CHIMICA ACTA, 2017, 467 :34-41
[54]   Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study [J].
Naylor, K. E. ;
Jacques, R. M. ;
Paggiosi, M. ;
Gossiel, F. ;
Peel, N. F. A. ;
McCloskey, E. V. ;
Walsh, J. S. ;
Eastell, R. .
OSTEOPOROSIS INTERNATIONAL, 2016, 27 (01) :21-31
[55]  
Niimi R, 2016, OSTEOPOROSIS INT, V27, P2845, DOI 10.1007/s00198-016-3581-z
[56]   The association between critical illness and changes in bone turnover in adults: a systematic review [J].
Orford, N. ;
Cattigan, C. ;
Brennan, S. L. ;
Kotowicz, M. ;
Pasco, J. ;
Cooper, D. J. .
OSTEOPOROSIS INTERNATIONAL, 2014, 25 (10) :2335-2346
[57]   Biochemical markers as predictors of rates of bone loss after menopause [J].
Rogers, A ;
Hannon, RA ;
Eastell, R .
JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (07) :1398-1404
[58]   Lower P1NP serum levels: a predictive marker of bone loss after 1 year follow-up in premenopausal systemic lupus erythematosus patients [J].
Seguro, L. P. C. ;
Casella, C. B. ;
Caparbo, V. F. ;
Oliveira, R. M. ;
Bonfa, A. ;
Bonfa, E. ;
Pereira, R. M. R. .
OSTEOPOROSIS INTERNATIONAL, 2015, 26 (02) :459-467
[59]  
Seibel Markus J, 2005, Clin Biochem Rev, V26, P97
[60]   Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate [J].
Seibel, MJ ;
Naganathan, V ;
Barton, I ;
Grauer, A .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (02) :323-329